Saturday, October 31, 2026

EUR/CHF Jumps By 1% In The Last 21 Sessions

EUR/CHF Jumps By 1% In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.51% for the last 21 sessions. At 22:06 EST on Thursday, 28 March, EUR/CHF (EURCHF) is $0.97.

EUR/CHF's yearly highs and lows, it's 7.663% up from its 52-week low and 2.683% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.03%, a positive 0.10%, and a positive 0.23%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.40% (last week), 0.24% (last month), and 0.23% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy: another leg higher needed for actual FX intervention to be deployed – ING. According to FXStreet on Wednesday, 27 March, "This may still be only a 'verbal intervention' range, with another USD/JPY leg higher needed for actual FX intervention to be deployed (perhaps closer to 155.00). "
  • Usd/jpy: the next major technical resistance after the 151.95-152.00 zone is not before 160.00 – BBH. According to FXStreet on Wednesday, 27 March, "In our view, it's only a matter of time before USD/JPY breaks higher because we anticipate a gradual BoJ tightening process and a more muted than currently priced-in Fed easing cycle.", "The next major technical resistance for USD/JPY after the 151.95-152.00 zone is not before 160.00 (April 1990 high)."
  • According to FXStreet on Wednesday, 27 March, "The Japanese Yen (JPY) continued to weaken against the US Dollar (USD), with USD/JPY reaching its highest level since 1990 near 152.00 early Wednesday. ", "After coming within a few pips of 152.00, USD/JPY edged slightly lower but stabilized above 151.50."
  • According to FXStreet on Thursday, 28 March, "This further contributes to keeping a lid on any meaningful appreciating move for the USD/JPY pair ahead of the release of the US Personal Consumption Expenditures (PCE) Price Index on Friday. ", "This is closely followed by the 150.00 psychological mark, which, if broken decisively, could make the USD/JPY pair vulnerable to accelerate the corrective decline further towards the 149.35-149.30 region en route to the 149.00 round figure."
  • Usd/jpy analysis: strong move ahead - 27 March 2024. According to DailyForex on Wednesday, 27 March, "Overall, according to economic calendar data, USD/JPY could take cues from medium-to-high US data, including the core PCE inflation index due later in the week. ", "There is no change in our technical view, as the overall trend for the USD/JPY currency pair remains bullish, and there will be no trend break without moving towards support levels at 149.80 and 148.00 respectively. "

More news about EUR/CHF (EURCHF).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com